Marino Marco Vito, Podda Mauro, Gomez Ruiz Marcos, Fernandez Carmen Cagigas, Guarrasi Domenico, Gomez Fleitas Manuel
Department of Surgery, Palermo University, Palermo, Italy.
Department of General and Digestive Surgery, Hospital Universitario Marquès de Valdecilla, Av. De Valdecilla 25, Santander, Cantabria, Spain.
J Robot Surg. 2020 Jun;14(3):493-502. doi: 10.1007/s11701-019-01018-w. Epub 2019 Aug 31.
Robotic-assisted pancreaticoduodenectomy (RPD) is progressively gaining momentum. It seems to provide some potential advantages over open approach. Unfortunately, only few studies investigated the impact of RPD on the oncologic outcomes. We performed a 1:1 case-matched comparison between two groups of 35 patients affected by a malignant tumor who underwent RPD and open (OPD) pancreaticoduodenectomy from August 2014 to April 2016. Operative time was longer in the RPD group compared to OPD (355 vs 262 min, p = 0.023), whereas median blood loss (235 vs 575 ml, p = 0.016) and length of hospitalization (6.5 vs 8.9 days, p = 0.041) were lower for RPD. A significant reduction of overall postoperative morbidity rate was found in the RPD group compared to the OPD group (31.4% vs 48.6% p = 0.034). No statistically significant difference was found between the two groups in terms of overall pancreatic fistula rate, R0 resection rate, and number of harvested lymph nodes. The overall and disease-free survival at 1 and 3 years were similar. RPD is a safe and effective technique. It reduces the estimated blood loss, the length hospital of stay and the rate of complications after pancreaticoduodenectomy, while preserving a good oncologic adequacy.
机器人辅助胰十二指肠切除术(RPD)正逐渐获得更多关注。与开放手术相比,它似乎具有一些潜在优势。遗憾的是,仅有少数研究探讨了RPD对肿瘤学结局的影响。我们对2014年8月至2016年4月期间接受RPD和开放胰十二指肠切除术(OPD)的两组各35例恶性肿瘤患者进行了1:1病例匹配比较。RPD组的手术时间比OPD组长(355分钟对262分钟,p = 0.023),而RPD组的术中失血量中位数(235毫升对575毫升,p = 0.016)和住院时间(6.5天对8.9天,p = 0.041)更低。与OPD组相比,RPD组术后总体并发症发生率显著降低(31.4%对48.6%,p = 0.034)。两组在总体胰瘘发生率、R0切除率和获取的淋巴结数量方面无统计学显著差异。1年和3年的总生存率及无病生存率相似。RPD是一种安全有效的技术。它减少了胰十二指肠切除术后的估计失血量、住院时间和并发症发生率,同时保持了良好的肿瘤学疗效。